CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie
  
AstraZeneca already has considerable manufacturing and R&D presence in the US, but its recently announced a new $50bn investment package.

More from Earnings

More from Business